Informações:
Falhas:
ID
34371
Descrição
Firmagon (Degarelix) Intermittent Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01512472
Link
https://clinicaltrials.gov/show/NCT01512472
Palavras-chave
Versões (1)
- 16/01/2019 16/01/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
16 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Prostate Cancer Recurrent NCT01512472
Eligibility Prostate Cancer Recurrent NCT01512472
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer Recurrent NCT01512472
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adenocarcinoma of prostate | Indication Hormone Therapy Intermittent
Item
histologically confirmed adenocarcinoma of the prostate for which intermittent endocrine treatment therapy is indicated
boolean
C0007112 (UMLS CUI [1])
C3146298 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0205267 (UMLS CUI [2,3])
C3146298 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0205267 (UMLS CUI [2,3])
PSA Level Criteria Fulfill
Item
psa level meeting both of these criteria:
boolean
C4086720 (UMLS CUI [1,1])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
C0243161 (UMLS CUI [1,2])
C1550543 (UMLS CUI [1,3])
PSA Level
Item
psa level of ≥ 5 ng/ml.
boolean
C4086720 (UMLS CUI [1])
Recurrence Post Therapeutic radiology procedure | Recurrence Post Cold Therapy | Prostate specific antigen measurement Quantity
Item
for patients with recurrence after radiotherapy or cryotherapy: patients should have a serum psa (two measurements) to be >2 ng/ml higher than a previously confirmed psa nadir.
boolean
C2825055 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,3])
C2825055 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0010412 (UMLS CUI [2,3])
C0201544 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0687676 (UMLS CUI [1,2])
C1522449 (UMLS CUI [1,3])
C2825055 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0010412 (UMLS CUI [2,3])
C0201544 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Serum testosterone measurement
Item
screening serum testosterone level above the lower limit of normal range defined as >2.2 ng/ml.
boolean
C0428413 (UMLS CUI [1])
Management Hormonal Prostate carcinoma | Surgical castration
Item
has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation)
boolean
C0376636 (UMLS CUI [1,1])
C0458083 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0007344 (UMLS CUI [2])
C0458083 (UMLS CUI [1,2])
C0600139 (UMLS CUI [1,3])
C0007344 (UMLS CUI [2])
5-alpha Reductase Inhibitors | Finasteride | Dutasteride
Item
has received therapy with the 5-alpha reductase inhibitors finasteride or dutasteride within 12 weeks and 25 weeks, respectively, prior to screening
boolean
C2936788 (UMLS CUI [1])
C0060389 (UMLS CUI [2])
C0754659 (UMLS CUI [3])
C0060389 (UMLS CUI [2])
C0754659 (UMLS CUI [3])